46 results about "Immunocytochemistry" patented technology

The present invention provides methods and compositions for isolating and detecting rare cells from a biological sample containing other types of cells. In particular, the present invention includes a debulking step that uses a microfabricated filters for filtering fluid samples and the enriched rare cells can be used in a downstream process such as identifies, characterizes or even grown in culture or used in other ways. The invention also include a method of determining the aggressiveness of the tumor or of the number or proportion of cancer cells in the enriched sample by detecting the presence or amount of telomerase activity or telomerase nucleic acid or telomerase expression after enrichment of rare cells. This invention further provides an efficient and rapid method to specifically remove red blood cells as well as white blood cells from a biological sample containing at least one of each of red blood cells and white blood cells, resulting in the enrichment of rare target cells including circulating tumor cells (CTC), stromal cells, mesenchymal cells, endothelial cells, fetal cells, stem cells, non-hematopoietic cells etc from a blood sample. The method is based upon combination of immuno-microparticles (antibody coated microparticles) and density-based separation. The final enriched target cells can be subjected to a variety of analysis and manipulations, such as flowcytometry, PCR, immunofluorescence, immunocytochemistry, image analysis, enzymatic assays, gene expression profiling analysis, efficacy tests of therapeutics, culturing of enriched rare cells, and therapeutic use of enriched rare cells. In addition, depleted plasma protein and white blood cells can be optionally recovered, and subjected to other analysis such as inflammation studies, gene expression profiling, etc.

Scanning and analysis of cytology and histology samples uses a flatbed scanner to capture images of the structures of interest such as tumor cells in a manner that results in sufficient image resolution to allow for the analysis of such common pathology staining techniques as ICC (immunocytochemistry), IHC (immunohistochemistry) or in situ hybridization. Very large volumes of such material are scanned in order to identify cells or clusters of cells which are positive or warrant more detailed examination, and if analysis at higher resolution is necessary, information regarding these positive events is transferred to a secondary microscope, such as a conventional scanning microscope, to allow further analysis and review of the selected regions of the slide containing the sample.

The invention relates to the field of liquid-based cytology immunocytochemistry, in particular to an immunohistochemical kit for auxiliary diagnosis of cervical cancer. Ready-to-use antibody working liquid is provided and prepared from an antibody reagent, bovine serum albumin, non-reductive sugar, betaine, cyclodextrin, a neutral inorganic salt, a surfactant and a preservative, wherein the antibody reagent is a reagent A or a reagent B; the reagent A is a phosphate buffer solution (PBS) of a p16<INK4a> monoclonal antibody and a Ki-67 monoclonal antibody; the reagent B is a PBS of horse radishperoxidase conjugated GaMIgG and an alkaline phosphatase conjugated goat anti-rabbit secondary antibody; and the pH value of the PBSs is 7.2-7.8.

The invention provides a database for guiding individualized medicine taking of a clinical tumor, a constructing method, a searching method and a device thereof. The constructing method of the database comprises the steps of acquiring common data resources of information of a biomarker which is related to tumor chemotherapy, targeted and immunization medicine taking guidance; screening and classifying the common data resources, and obtaining key field and attribute of biomarker information; performing grade classification and dividing on clinical evidence information; establishing a deciphering database structure framework of the biomarker which is related with tumor chemotherapy, targeting and immunization; and recording the information which corresponds with the key field to the corresponding field position of the database structure framework for obtaining the database for guiding individualized medicine taking of the clinical tumor. According to the method, the multi-layer biomarkers which are detected through detecting technology such as high-flux sequencing and immunocytochemistry are comprehensively considered, thereby covering information at aspects of tumor chemotherapy, targeting and immunization medicine taking guidance, and making knowledge resource reserving for clinical medical guidance for individualized medicine taking of the tumor.

The invention provides a method for isolating and identifying disseminated liver cancer cells. The method is based on a de-ASGPR on a liver cancer cell membrane and in the method, a ligand or antibody of the de-ASGPR is combined with a liver cancer cell, a bead is used to mark the liver cancer cell indirectly for positive isolation and enrichment, a immunocytochemistry method or a flow cytometry is adopted to identify and inspect to judge whether any liver cancer cells exist in the sample. The method can be used for the diagnosis, metastasis, recurrent forecasting and efficacy monitoring of liver cancer, can be used to detect disseminated liver cancer cells and is high in sensibility, good in specificity and convenient to operate.

The present invention describes a dissociated cell culture system comprising cells of the hippocampus, one of the brain areas affected by Alzheimer's Disease (AD) or amyloid beta-related diseases. This culture system comprises hippocampal neuronal and glial cells from animal models of AD, particularly, but not limited to, double transgenic mice expressing both the human APP mutation (K670N:M671L) (mAPP), and the human PS1 mutation (M146L) (mPS1), and serves as a powerful tool for the screening and testing of compounds and substances, e.g., drugs, for their ability to affect, treat, or prevent AD or β-amyloid-related diseases. The effects of a test substance on the cells in this culture system can be quantitatively assessed to determine if the test substance affects the cells biochemically and / or electrophysiologically, and / or optically, and / or immunocytochemically. The present in vitro culture system is advantageous for AD drug screening, because it is rapid and efficient. By contrast, even in the fastest animal model of AD, pathology does not start before the end of the second month. If such in vivo animal models are used, it is necessary to wait at least the two month time duration or longer to test for drug efficacy for AD treatment or prevention. At the same time the present invention provides a tool for production of amyloid-beta that can be used for electrophysiological, behavioral, and toxicological studies.

The invention relates to the plant gene engineering field, particularly a plant leaf promoter conferring vascular-specific expression, a plant expression vector comprising the promoter and a transformant. The invention also relates to the application of the promoter in the plant gene engineering. The nucleotide sequence of the plant leaf promoter conferring vascular-specific expression is shown as SEQ ID No:1. The inventor subjects the plant expression vector with the promoter DNA sequence and a GUS gene to genetic transformation mediated through agrobacterium tumfaciens to obtain transgenic plants. According to identification by immunocytochemistry, the GUS gene only confers vascular -specific expression on rice leaves, therefore, it is supposed that the promoter provided in the invention can drive extrinsic stress-resistant genes to confer vascular -specific expression on plant leaves, so that the promoter can be directionally used for cultivate new transgenic plants with high safety.

The invention discloses a pathological specimen slice immunocytochemistry operation method and a pathological specimen slice immunocytochemistry operation system. The pathological specimen slice immunocytochemistry operation method comprises: slicing pathological specimen paraffin, baking the pathological specimen paraffin slice, removing the paraffin from the pathological specimen paraffin slice, carrying out antigen repair on the pathological specimen slice, staining the pathological specimen slice, adding antibodies to the pathological specimen slice in a dropwise manner, carrying out color developing on the pathological specimen slice, counterstaining the pathological specimen slice, sealing the pathological specimen slice, carrying out microscopic examination, and other steps. According to the present invention, staining is firstly performed with hematoxylin and then the antibodies I and II are added in the dropwise manner, such that the color developing of the antibodies can be easily achieved, the size and the position of the tissue can be easily grasped by sequentially carrying out the staining and the antibody adding in the dropwise manner, the position deviation during the antibody adding in the dropwise manner is reduced, the normative experiment operation can be easily performed, the strong practical value can be provided, the actual waste can be effectively avoided, and the error of the experiment data can be substantially reduced.

The invention provides a technology and method for preparing high throughput needle biopsy tissue chip. The method comprises the following steps: collecting 42 residual paraffin-embedded tissue samples of needle biopsy of patients who have been diagnosed as the breast cancer patients through pathological examination on mammary gland needle biopsy tissues; taking the corresponding normal pathological HE stained sections as the guide, cutting the paraffin-embedded tissue sections (1mm to 4mm) corresponding to the cancer parts of the HE-stained sections, preparing paraffin-embedded tissue cores, preparing breast cancer needle biopsy tissue arrays by utilizing a tissue chip instrument, cutting paraffin into slices, and preparing paraffin-embedded tissue chip of breast cancer needle biopsy tissue. The prepared needle biopsy tissue chip can be applied to molecular medical research of related diseases such as immunocytochemistry, in-situ hybridization, and the like.

The invention discloses a production method of a cell block paraffin section for fully presenting the position of a malignant cell. The method comprises the following steps: firstly, acquiring a primary cell sample and performing centrifugation sediment on the primary cell sample, so as to obtain a secondary cell sample; after the secondary cell sample is fixed, placing the secondary cell sample into a tissue dehydration box in a manner of vertical dividing from the middle for dehydration, transparentizing and waxing in sequence, so as to obtain a cell fixed sample; and vertically placing thecell fixed sampled into a tissue embedding box for embedding by taking a plane of section as a bottom surface, so as to form the section finally. Each section produced by the method can present the same cell hierarchical structure, so that the malignant cell appears at the same position of each section, a phenomenon that the malignant cell is located unreliably and even disappears in continuous sections is avoided, a comparative analysis when various antibodies are labeled in immunocytochemistry is facilitated, and cytopathology doctors can be effectively assisted to judge the source and the type of a malignant tumor, and therefore, the accuracy rate of cytopathological diagnosis is improved, a clinical application effect is good, and the practical value is high.

The invention relates to a breast cancer circulating tumor cells detection system and a kit, the detection system comprises a breast cancer circulating tumor cells capture system, a magnetic sorting apparatus and an analysis counting system; the breast cancer circulating tumor cells capture system comprises a functional enrichment box, an immunization magnetic microballoon, a cell incubation apparatus and a fluorescence coloring agent; the automatic magnetic sorting apparatus is used for enriching the tumor cells and performing fluorescence dyeing; the analysis counting system includes a fluorescence microscope and a high flux cell image analyzer; and the kit comprises the immunization magnetic microballoon and the fluorescence coloring agent. According to the invention, a magnetic cell sorting technology and an immunocytochemistry technology are combined for detecting peripheral blood circulation tumor cells, analysis and counting are carried out on the tumor cells by the analysis counting system, and the analysis on the molecule and gene aspects of the circulating tumor cells can be realized with high efficiency.

Anti-peptide antibodies (APAs) are extremely important tools for biomedical research. Many important techniques, such as immunoblots, ELISA immunoassays, immunocytochemistry, and protein microarrays are intrinsically linked to APA function and completely dependent on APA quality. Unfortunately, not all commercially-available APAs have good antigen binding characteristics; as a result, researchers are often unable to perform high quality protein analysis experiments. This disclosure describes a new method for the scalable production of polyclonal APAs using recombinant antigens. These recombinant peptide antigens have several advantages over traditional peptide antigens which improve the ease and speed of antibody production. The recombinant antigens can be scalably produced and purified much faster than traditional synthetic peptide-conjugates. These recombinant antigen-carriers are designed to specifically aggregate in vivo after administration into the host; this aggregation greatly enhances immunogenicity and may eliminate the need for the use of chemical adjuvants which cause physical irritation and discomfort to the host.

The invention provides compositions and methods for the detection of targets in a sample; in particular, an in situ hybridization (ISH) sample. Probes and detectable labels may be provided in multiple layers in order to increase the flexibility of a detection system, and to allow for amplification to enhance the signal from a target. The layers may be created by incorporating probes and detectable labels into larger molecular units that interact through nucleic acids base-pairing, including peptide-nucleic acid (PNA) base-pairing. Optional non-natural bases allow for degenerate base pairing schemes. The compositions and methods are also compatible with immunohistochemistry (IHC), immunocytochemistry (ICC), flow cytometry, enzyme immuno-assays (EIA), enzyme linked immuno-assays (ELISA), blotting methods (e.g. Western, Southern, and Northern), labeling inside electrophoresis systems or on surfaces or arrays, and precipitation, among other general detection assay formats. The invention is also compatible with many different types of targets, probes, and detectable labels.

The invention discloses a mouse anti-human CD61 monoclonal antibody hybridoma cell line, a monoclonal antibody and a preparation method and application thereof and a flow cytometry detection reagent, and belongs to the technical field of biological engineering. According to the mouse anti-human CD61 monoclonal antibody hybridoma cell line, human peripheral blood leukocytes are used as an immunogen for immunizing Balb / c mice; a cell fusion technology is adopted and hybridoma cells are screened by utilizing an immunocytochemistry and a flow cytometry indirect immunofluorescent method; an antibody generated by monoclonal hybridoma cells is subjected to specific identification by applying an immunoprecipitation-mass-spectrometric method; Western Blot proves that one hybridoma cell line IID5G8 capable of stably secreting a mouse anti-human CD61 monoclonal antibody is obtained and a preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 13300. The monoclonal antibody is prepared by adopting an animal in-vivo induction method; a heavy chain of the antibody is identified to be IgG1 and a light chain is identified to be kappa type; after the antibody is purified, an FITC (Fluorescein Isothiocyanate) label can be used for detecting antigen expression of human peripheral blood platelets CD61 by utilizing flow cytometry direct-labeling immunofluorescence.

The invention relates to a medical appliance, in particular to a pathology specimen soaking device and a using method thereof. A specimen soaking plate can be moved up and down in a soaking bucket, can be fixed at a position with a certain height in the soaking bucket, and is provided with multiple specimen needle mounting holes. The bottom of the specimen soaking plate is provided with specimen soaking plate array slots. A specimen is completely soaked in a specimen soaking liquid when the specimen is soaked. According to the pathology specimen soaking device and the using method thereof, thesoaking effect is improved, the pathological diagnosis, the immunocytochemistry, and the molecular detection structure are more accurate, the specimen is prevented from deterioration caused by incomplete soaking, inversion of the specimen soaking plate during use is avoided, the specimen is fixed firmly and will not fall off, and a push-pull rod is connected to the specimen soaking plate to facilitate the picking and placing of the specimen. The material of the specimen soaking plate is PTFE which is not easy to stick to grease and is easy to clean after using. A bucket cover is provided to prevent the scent of the soaking liquid from spreading during the soaking process, so that environmental pollution will be prevented and the health of the medical staff will not be affected. The usingmethod is also simpler and more standardized.

The invention relates to a monoclone antibody of ARD1 and application thereof, in particular to the monoclone antibody aiming at ARD1 protein and excreted by a hybridoma of which the preserving number is CGMCC NO.2354 or CGMCC NO.2355, and a hybridoma cell line for excreting the antibody. The monoclone antibody has the characteristics of strong specificity and high sensitivity, and can be applied to immunological detections of immunohistochemistry, immunocytochemistry, immunoprecipitation, immunoblotting, enzyme-linked immunosorbent assay, and the like, thus the monoclone antibody can detect the ARD1 expression levels of tumors such as colon cancer, gastric cancer, esophageal cancer, and the like and various tumor cell lines, and is further applied to assistant diagnosis and correlative experimental investigations on the various tumors, and instructing clinical treatments.

A method combined with its necessary container package that facilitates unique processing of microscope slides in a reagent solution is disclosed. This invention has not been described elsewhere. The container package is a partitioned box with each compartment fitting one standard microscope slide. The slides are immersed in a staining solution and the container package is covered with a lid. The container package and slides / staining solution are placed on a standard laboratory apparatus and rocked or agitated for an arbitrary incubation time. The method and its necessary container package provides a means for more reproducibility and sensitivity of results than the prior art that is critical for accurate scientific findings.

The establishing process of mesoblastic nephroma animal model includes the following steps: primary culture of embryo muscle cell of mammal; subculture after the cell grows to fuse; extracorporeal culture for 3-8 months to obtain cloning cell in the culture and eternal tumor cell line; passaging for several times after malignant cell transformation to obtain monoclinic cell strain via monoclonal culture; nude mouse hypodermic transplantation of the monoclinic cell strain; identifying the tumor cell strain by means of immunocytochemistry method or molecular biological method; transplanting the obtained fibrosarcoma cell strain to nude mouse renal diolame to obtain the mesoblastic nephroma animal model. The mesoblastic nephroma animal model provides the research of mesoblastic nephroma pathogenesis and treatment with technological platform.

The invention belongs to the technical field of hypoxic blood-testis-barrier permeability action mechanisms, and discloses a method for constructing a mouse model of an action mechanism in hypoxic blood-testis-barrier permeability. The method comprises the following steps: establishing a hypoxic induced C57BL / 6 and testicular mTOR single-gene knockout mouse hypoxic blood-testis-barrier permeability model, separating and collecting mTOR gene knockout mouse and C57BL / 6 mouse seminiferous tubule primary support cell lines and mouse support cell strains, and applying technologies like western blot, immunocytochemistry and qPCR in vitro to prove a potential molecular mechanism of the regulating effect of mTOR on JAM-B. According to the invention, the protective effect of a hypoxic inhibitory activated metabolic balance marker molecule, namely the mTOR in hypoxic blood-testis-barrier permeability and the molecular mechanism of the mTOR on expression of activated JAM-B are defined; and a theoretical basis and a treatment strategy are provided for treatment of the hypoxic blood-testis-barrier permeability.

The invention belongs to the technical field of inhibition of hypoxia spermatogenesis reduction, and discloses a detection method for inhibition of hypoxia spermatogenesis reduction of DR5 by VHA. VHAgene knockout mice and C57BL / 6 mice are used as research objects, and a hypoxia spermatogenesis reduction model is constructed through hypoxia induction. A seminiferous tubule seminiferous cell of anexperimental mouse is separated to serve as a research object. Hypoxic in-vitro stimulation is conducted, and the regulating effect and the molecular mechanism of VHA for inhibiting seminiferous cellexpression DR5 are verified through western blot, immunocytochemistry and qPCR technologies. According to the detection method for inhibiting DR5 spermatogenesis reduction under oxygen deficit by VHA, which is provided by the invention, the effect of hypoxic inhibition of VHA in hypoxic spermatogenesis reduction and the molecular mechanism of hypoxic inhibition of VHA in inhibition of DR5 expression are clarified, and a necessary theoretical basis and a new treatment strategy are provided for treatment of hypoxic spermatogenesis reduction.

The invention relates to the technical field of cell chromogenic reagents, in particular to an immune cell chemical labeling chromogenic kit for auxiliary diagnosis of cervical cancer. The kit comprises a ready-to-use antibody working solution, a reagent solution C, a reagent solution D, a reagent solution E, a reagent solution F and a reagent solution G; the ready-to-use antibody working solution comprises an antibody reagent, bovine serum albumin, non-reducing sugar, fish skin gelatin, a preservative proclin-950, tender leaf green pigment, polyethylene glycol, casein, a surfactant, 4-aminoantipyrine and sodium chloride, and the antibody reagent comprises a reagent solution A and a reagent solution B. The kit can be used for cervical decellularization and can also be used for tissue staining. The blue returning mode is newly created, the blue returning effect is better than that of kits of other manufacturers in the market, the sheet sealing mode is simpler, and the experiment time is greatly shortened.

The invention discloses an evaluation system for stress responses of sea horses. The evaluation system is characterized by comprising 26 indexes in the five aspects of the outside index, immunocytochemistry, antibacterial peptide gene, immune factors and blood cells, symptom intervals of the 26 indexes and corresponding scores, total points and evaluation conclusions. The evaluation system and method for the stress responses of the sea horses involve the growth indexes, the physiological indexes and the immune indexes, and systematically evaluate the stress responses of the sea horses from behaviors, dissection and the molecular level, the indexes can detect the stress responses of the sea horses in different aspects and multiple levels, the evaluation system can reflect the trigger time,the response mode and the intensity of the stress, and the evaluation system can help people master stress response characteristics of sea horses to different stress factors.

The invention relates to a method for the pure culture of human pituitary prolactinoma cells, which is characterized in that 'moderate enzyme digestion and filtration' is adopted to remove fibroblasts and 'red blood cell lysis solution' is adopted to remove red blood cells, and except the two kinds of the cells, the remained cells are human pituitary prolactinoma cells, wherein the method comprises the following steps: (1), putting tumor tissues into culture solution; (2), cutting tissue blocks into small pieces; (3), digesting the small pieces by pancreatins; (4), filtering the digested substance through a cell sieve and terminating the digestion; (5), adding the red blood cell lysis solution and re-suspending the cells; (6), removing the red blood cell lysis solution, (7), absorbing the culture solution and adding the culture solution into a blood cell counting plate, then counting; and (8), inoculating the cells into a 24-hole culture plate by each hole having 1 x 10<6> cells, and putting the culture plate in a cell incubator. The mentod is easy and convenient to operate and can simultaneously remove fibroblasts and the red blood cells, the obtained pituitary adenoma cells are authenticated through an immunocytochemistry method, and the cell purity is high and is close to 100 percent.

The invention discloses a lymph node metastasis carcinoma diagnostic method based on immunomagnetic beads and a kit. According to the method, the based immunomagnetic beads refer to magnetic nanospheres modified with anti-epithelial adhesion molecular antibodies. The method comprises the following steps: adding immunomagnetic beads into a paracentesis specimen for incubating for 5-10 minutes, performing magnetic separation, washing, smearing, staining and other steps, and realizing sensitive detection and visualization diagnosis of metastatic cancer cells. The method disclosed by the invention is high in capture efficiency and specificity and small in influence of cancer cell morphometry, and the total diagnosis accuracy rate is 99.1%. According to the method disclosed by the invention, distinctive diagnosis of lymphoid reactive hyperplasia, malignant lymphoma and metastatic carcinoma is realized, the cell smear subjected to magnetic separation can be directly used for identifications such as Wright staining, immunocytochemistry, immunohistochemistry and fluorescent in-situ hybridization, and the method becomes a powerful means for diagnosis of metastatic cancers and has important medical significances.

Provided herein are compositions comprising: a scaffold polymer having one or more acryloyl groups or one or more methacryloyl groups; optionally a porogen and a crosslinking agent, compositions that upon crosslinking form a hydrogel for use in cell encapsulation and methods for immunocytochemistry of encapsulated cells. Scaffold polymers used are selected from: Poly(ethylene glycol) diacrylate (PEGDA); Poly(ethylene glycol) dimethylacrylate (PEGDMA); Poly(ethylene glycol) methyl ether acrylate (PEGMEA); Poly(ethylene glycol) methacrylate (PEGMA); and Poly(ethylene glycol) methyl ether methacrylate (PEGMEMA), and porogens selected from: Poly(ethylene glycol) (PEG); Chitosan; Agarose; Dextran; Hyaluronic acid; Poly(methyl methacrylate) (PMMA); Cellulose and derivatives thereof; Gelatin and derivatives thereof; and Acrylamide and derivatives thereof. The invention also provides, at least in part, compositions for forming a porous hydrogel around a cell suitable for immunostaining of cells within the hydrogel.

The invention relates to a method for primary culture of human umbilical vessel smooth muscle cells. The method comprises the following culture steps of: 1) cleaning blood on human umbilical cord, separating umbilical vein, and transferring to a sterile culture vessel; 2) cutting the blood vessel along the vertical axis direction, and removing endothelial cells while maintaining the internal membrane surface of the blood vessel upwards; 3) cutting the blood vessel into 5mm*5mm blocks, sucking and transferring to a culture bottle and uniformly paving on a bottle bottom; 4) inverting the culture bottle, and adding a DMEM (Eagle's minimal essential medium) culture liquid containing 20% fetal bovine serum; 5) placing the culture bottle in a 37 DEG C incubator containing 5% CO2, after the tissue blocks cling to the wall 4-6 hours later, carefully overturning the culture bottle, thus immersing the tissue blocks in the culture liquid, and standing and culturing; and 6) exchanging the liquid once every 3 days, and carrying out morphological and immunocytochemical identification on the cells when 3-5 generations of cells are generated.

The invention discloses an establishing method of an ERalpha36 knock-down PC12 cell strain. An shRNA (short hairpin ribonucleic acid) technology is used, an ERalpha36-shRNA transfected PC12 cell is utilized to establish the ERalpha36 knock-down PC12 cell strain. Immunocyte fluorescence, immunocytochemistry and Western blot technologies are utilized to detect the ERalpha36 in the cell strain, and the fact proves that the cell strain is successfully established. A growth curve and doubling time of the cell are determined. The establishment of the ERalpha36 knock-down PC12 cell strain provides a powerful experimental material for researching functions of the ERalpha36 in the central nervous system.

A method of analysing a sample for at least one analyte in histology, such as histopathology, or cytopathology, particularly for immunohistochemistry or immunocyto-chemistry is described. The method comprising contacting the sample with at least one targeting moiety or probe, wherein each different targeting moiety or probe of the at least one targeting moiety or probe specifically binds a different analyte of the at least one analyte. Each different targeting moiety or probe of said at least one targeting moiety or probe is conjugated to a different luminescent particle. Detecting a signal from the luminescent particle associated with the at least one targeting moiety bound to the sample. The presence or amount of at least one analyte may thereby be detected in the sample.

The invention provides a method for promoting dermal papilla cells to induce hair regeneration through HHORSCs exosomes. The method for promoting dermal papilla cells to induce hair regeneration through HHORSCs exosomes comprises the following steps that S1, human dermal papilla cells and human hair follicle outer root sheath cells are cultured and separated from a human scalp sample; s2, evaluating a specific marker by using flow cytometry and an immunocytochemistry technology; s3, separating blood platelets from the human hair follicle outer root sheath cells and the human umbilical cord blood by using an ultracentrifugation technology, and further separating exosomes; s4, detecting a specific marker of the exosome by using a western blot method; s5, analyzing the particle size and distribution of the exosome through a nano-particle tracking analysis technology; and S6, evaluating the influence of exosomes with different concentrations on the regeneration capacity by using different methods such as a proliferation test and a migration test. The method for promoting dermal papilla cells to induce hair regeneration by using the HHORSCs exosome has the advantages of improving alopecia and realizing hair regeneration.